Abstract
Recent data suggest a novel role of progesterone in breast cancer etiology involving the progesterone metabolites 3α-dihydroprogesterone (3αHP), 5α-dihydroprogesterone (5αP), and 20α-dihydroprogesterone (20αHP). Accurate and precise measures of progesterone metabolites are needed for etiologic studies of hormonally related cancers. We have developed a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method to measure five hormones, including progesterone, its precursor pregnenolone, and three progesterone metabolites, 5αP, 3αHP, and 20αHP. Hormone levels were measured in serum from 20 healthy volunteers (7 men, 5 premenopausal women, and 8 postmenopausal women). Two blinded, randomized aliquots per individual were assayed in each of four batches. The coefficients of variation (CV) and intraclass correlation coefficients (ICC) were calculated from the individual components of variance. The overall laboratory CVs were <3% and ICCs were uniformly high (>98%) for all hormones measured across sex/menopausal status groups. Our HPLC-MS/MS assay of progesterone metabolites demonstrated excellent sensitivity, laboratory reproducibility, and interindividual variation, suggesting that this serum assay is suitable for epidemiologic research. The high sensitivity of the assay, and thus the ability to quantify concentrations among postmenopausal women and men, further supports that this novel assay is suitable for studies of serum progesterone metabolite concentrations and risk of breast cancer or other hormonally related cancer.
Acknowledgments
This study was supported by the Intramural Research Program of the National Institutes of Health, Division of Cancer Epidemiology and Genetics, National Cancer Institute, (Grant/Award Number: ‘ZIA CP010126-14’). The authors gratefully acknowledge Norma Diaz-Mayoral, Gretchen Gierach, Barbara Fuhrman, and Cher Dallal for assistance with sample acquisition.
Conflict of interest statement: The authors have nothing to disclose.
References
1. Endogenous hormones and breast cancer collaborative group, Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, Rollison DE, Dorgan JF, Brinton LA, Overvad K, Kaaks R, Trichopoulou A, Clavel-Chapelon F, Panico S, Duell EJ, Peeters PH, Rinaldi S, Fentiman IS, Dowsett M, Manjer J, Lenner P, Hallmans G, Baglietto L, English DR, Giles GG, Hopper JL, Severi G, Morris HA, Hankinson SE, Tworoger SS, Koenig K, Zeleniuch-Jacquotte A, Arslan AA, Toniolo P, Shore RE, Krogh V, Micheli A, Berrino F, Barrett-Connor E, Laughlin GA, Kabuto M, Akiba S, Stevens RG, Neriishi K, Land CE, Cauley JA, Lui LY, Cummings SR, Gunter MJ, Rohan TE, Strickler HD. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709–22.10.1038/bjc.2011.254Search in Google Scholar
2. Endogenous hormones and breast cancer collaborative group, Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, Barricarte A, Berrino F, Krogh V, Sieri S, Brinton LA, Dorgan JF, Dossus L, Dowsett M, Eliassen AH, Fortner RT, Hankinson SE, Helzlsouer KJ, Hoffman-Bolton J, Comstock GW, Kaaks R, Kahle LL, Muti P, Overvad K, Peeters PH, Riboli E, Rinaldi S, Rollison DE, Stanczyk FZ, Trichopoulos D, Tworoger SS, Vineis P. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013;10:1009–19.10.1016/S1470-2045(13)70301-2Search in Google Scholar
3. Endogenous hormones and prostate cancer collaborative group, Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008;100:170–83.10.1093/jnci/djm323Search in Google Scholar
4. Black A, Pinsky PF, Grubb RL, Falk RT, Hsing AW, Chu L, Meyer T, Veenstra TD, Xu X, Yu K, Ziegler RG, Brinton LA, Hoover RN, Cook MB. Sex steroid hormone metabolism in relation to aggressive prostate cancer. Cancer Epidemiol Biomarkers Prev 2014;23:2374–82.10.1158/1055-9965.EPI-14-0700Search in Google Scholar
5. Brinton LA, Key TJ, Kolonel LN, Michels KB, Sesso HD, Ursin G, Van Den Eeden SK, Wood SN, Falk RT, Parisi D. Prediagnostic sex steroid hormones in relation to male breast cancer risk. J Clin Oncol 2015;33:2041–50.10.1200/JCO.2014.59.1602Search in Google Scholar
6. Brinton LA, Richesson D, Leitzmann MF, Gierach GL, Schatzkin A, Mouw T, Hollenbeck AR, Lacey JV Jr. Menopausal hormone therapy and breast cancer risk in the NIH-AARP diet and health study cohort. Cancer Epidemiol Biomarkers Prev 2008;17:3150–60.10.1158/1055-9965.EPI-08-0435Search in Google Scholar
7. Fournier A, Berrino F, Riboli E, Avenel E, Clavel-Chapelon F. Breast cancer risk in relation to different types of hormone replacement therapy in the E3N-EPIC cohort. Intl J Cancer 2005;114:448–54.10.1002/ijc.20710Search in Google Scholar
8. Collaborative group on the epidemiologic studies of ovarian cancer, Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R. Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 2015;385:1835–42.10.1016/S0140-6736(14)61687-1Search in Google Scholar
9. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck A, Park Y, Brinton LA. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk? Int J Cancer 2013;132:417–26.10.1002/ijc.27623Search in Google Scholar PubMed PubMed Central
10. Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol 2014;142:83–9.10.1016/j.jsbmb.2013.05.001Search in Google Scholar PubMed PubMed Central
11. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Acensao J, Rodabough RJ, Rosenberg CA, Taylor VM, Harris R, Chen C, Adams-Campbell LL, White E, Women’s health initiative investigators. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350:991–1004.10.1056/NEJMoa032071Search in Google Scholar PubMed
12. Hildebrand JS, Jacobs EJ, Campbell PT, McCullough ML, Teras LR, Thun MJ, Gapstur SM. Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev 2009;18:2835–41.10.1158/1055-9965.EPI-09-0596Search in Google Scholar PubMed
13. Johnson JR, Lacey JV, DeAnn Lazovich D, Geller MA, Schairer C, Schatzkin A, Flood A. Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2009;18:196–203.10.1158/1055-9965.EPI-08-0596Search in Google Scholar PubMed PubMed Central
14. Lange CA. Challenges to defining a role for progesterone in breast cancer. Steroids 2008;73:914–21.10.1016/j.steroids.2007.12.023Search in Google Scholar PubMed PubMed Central
15. Lange CA, Yee D. Progesterone and breast cancer. Womens Health 2008;4:151–62.10.2217/17455057.4.2.151Search in Google Scholar
16. Wiebe JP, Zhang G, Welch I, Cadieux-Pitre HT. Progesterone metabolites regulate induction, growth, and suppression of estrogen- and progesterone-receptor-negative human breast cell tumors. Breast Cancer Res 2013;15:R38.10.1186/bcr3422Search in Google Scholar PubMed PubMed Central
17. Pawlak KJ, Zhang G, Wiebe JP. Membrane 5-alpha-pregnane-3,20-dione (5-alphaP) receptors in MCF-7 and MCF-10A breast cancer cells are up-regulated by estradiol and 5-alphaP and down-regulated by the progesterone metabolites, 3-alpha-dihydroprogesterone and 20-alpha-dihydroprogesterone, with associated changes in cell proliferation and detachment. J Steroid Biochem Mol Biol 2005;97:278–88.10.1016/j.jsbmb.2005.05.014Search in Google Scholar PubMed
18. Pasqualini JR, Chetrite G. The anti-aromatase effect of progesterone and of its natural metabolites 20-alpha- and 5-alpha-dihydroprogesterone in the MCF-7-aro breast cancer cell line. Anticancer Res 2008;28:2129–33.Search in Google Scholar
19. Zhang Y, Nadeau M, Faucher F, Lescelleur O, Biron S, Daris M, Rheaume C, Luu-The V, Tchernof A. Progesterone metabolism in adipose cells. Mol Cell Endocrinol 2009;298:76–83.10.1016/j.mce.2008.09.034Search in Google Scholar PubMed
20. Kinoshita T, Honma S, Shibata Y, Yamashita K, Watanabe Y, Maekubo H, Okuyama M, Takashima A, Takeshita N. An innovative LC-MS/MS-based method for determining CYP17 and CYP19 activity in the adipose tissue of pre- and postmenopausal and ovariectomized women using 13C-labeled steroid substrates. J Clin Endocrinol Metab 2014;99:1339–47.10.1210/jc.2013-3715Search in Google Scholar PubMed
21. Missmer SA, Eliassen AH, Barbieri RL, Hankinson SE. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 2004;96:1856–65.10.1093/jnci/djh336Search in Google Scholar PubMed
22. Eliassen AH, Missmer SA, Tworoger SS, Spiegelman D, Barbieri RL, Dowsett M, Hankinson SE. Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 2006;98:1406–15.10.1093/jnci/djj376Search in Google Scholar PubMed
Supplemental Material
The online version of this article (DOI: 10.1515/hmbci-2015-0026) offers supplementary material, available to authorized users.
©2015 by De Gruyter
